Platelet Glycoprotein IIb/IIIa Inhibitors in Percutaneous Coronary Intervention: Focus on the Pharmacokinetic-Pharmacodynamic Relationships of Eptifibatide

Author： Gilchrist I.C.  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.42, Iss.8, 2003-01, pp. : 703-720

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions: a pharmacological and clinical review

By Anne Ganeshkumar   Gruberg Luis  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 2, 2004-02 ,pp. : 335-348

Informa Healthcare

Access to resources Recommend Favorite

Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes

By  

Heart Drug, Vol. 1, Iss. 2, 2004-11 ,pp. : 103-109

Karger

Access to resources Recommend Favorite

Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa

By Tcheng James E   O’Shea J Conor  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 8, 2002-08 ,pp. : 1199-1210

Informa Healthcare

Access to resources Recommend Favorite

Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention?

By Doggrell Sheila  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 8, 2003-08 ,pp. : 1431-1433

Informa Healthcare

Access to resources Recommend Favorite

Optimal Use of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Patients Undergoing Percutaneous Coronary Interventions

By Starnes H. Benjamin   Patel Ankit A.   Stouffer George A.  

Drugs, Vol. 71, Iss. 15, 2011-10 ,pp. : 2009-2030

Adis International

Access to resources Recommend Favorite